Last updated 12 days ago
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
147 patients around the world
Available in Argentina, United States
This study consists of a 16-week Double-blind Period and a 100-week Long-term Extension
(LTE) composed of a 40-week Main Extension and a 60-week Optional Extension.
Merck Sharp & Dohme LLC
3Research sites
147Patients around the world
This study is for people with
Hidradenitis suppurativa
Requirements for the patient
To 75 Years
All Gender
Medical requirements
- Has signs and symptoms of hidradenitis suppurativa (HS) for ≥ 6 months and a clinical diagnosis of HS at screening.Has moderate or severe HS.Has a history of inadequate response to a course of systemic antibiotics for treatment of HS or intolerance to or has a contraindication to systemic antibiotics for treatment of HS.Has ≤20 draining tunnel count at Screening and Randomization.
- Has other active skin conditions that may interfere with the assessment of HS.Has any immune-mediated inflammatory condition that is not well controlled and which may potentially require biologic therapy.Has a transplanted organ and requires continued systemic immunosuppression.Has a history of cancer (except fully treated non-melanoma skin cancers or cervical carcinoma in situ after complete surgical removal) within the last 5 years.Has known allergies, hypersensitivity, or intolerance to tulisokibart or its excipients.
Sites
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Recruiting
Psoriahue Medicina Interdisciplinaria - CABA, Buenos Aires
Recruiting
Derma Internacional S.A.
Recruiting
SponsorMerck Sharp & Dohme LLC
Study typeInterventional
Conditions
Hidradenitis suppurativa
Requirements
To 75 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06956235
